Search

Displaying results 1551 - 1560 of 10000 in total
  1. Drug

    Glecaprevir

    go.drugbank.com/drugs/DB13879
    ApprovedInvestigational

    The combinations of amino acid substitutions at NS3 position Y65H and D/Q168 also results in greater reductions in glecaprevir susceptibility, and NS3 Q80R in genotype 3a patients also leads to glecaprevir … In cell cultures, the emergence of amino acid substitutions at NS3 resistance-associated positions A156 or D/Q168 in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility to glecaprevir [FDA

    Mixtures: MAVİRET 100 MG/40 MG FİLM KAPLI TABLET, 84 ADET, MAVIRET® 100/40 MG TABLETAS RECUBIERTAS
  2. Drug

    Taurine

    go.drugbank.com/drugs/DB01956
    ApprovedInvestigationalNutraceutical

    Taurine, whose chemical name is 2-aminoethanesulfonic acid, is one of the most abundant amino acids in several organs. It plays important role in essential biological processes. … [A31396] This conditional amino acid can be either be manufactured by the body or obtained in the diet mainly by the consumption of fish and meat.

    Mixtures: SMOFKABIVEN EF, Numeta G 13 % E Emulsion zur Infusion
  3. Drug

    Atovaquone

    go.drugbank.com/drugs/DB01117
    ApprovedInvestigational

    Atovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.

    Mixtures: Malarone 250 mg/100 mg Filmtabletten, Atovaquon/Proguanilhydrochlorid STADA 250 mg/100 mg FilmtablettenProducts: ATOVAQUONE E PROGUANILE SANDOZ
  4. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    It has since been withdrawn from the market in the wake of the phase 3 OCEAN trial which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and [dexamethasone … [A230143,L32173] Melphalan flufenamide was granted FDA approval on 26 February 2021.[L32173].

  5. Drug

    Bazedoxifene

    go.drugbank.com/drugs/DB06401
    ApprovedInvestigational

    It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. … the prevention of postmenopausal osteoporosis in women.

    Mixtures: DUAVIVE 20 mg/0.45 mg modified - release tablets, DUAVİVE 0.45 MG/20 MG DEĞİŞTİRİLMİŞ SALIMLI TABLET, 30 TABLET
  6. Drug

    TrenibotulinumtoxinE

    go.drugbank.com/drugs/DB19082
    Approved

    [L64118] It is the first and only rapid-onset, short-duration botulinum neurotoxin serotype E approved in Europe.[L64118] … TrenibotulinumtoxinE is a botulinum neurotoxin serotype E, produced in *Clostridium botulinum*, used for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

    Synonyms: BOTULINUM NEUROTOXIN SEROTYPE E (BONT/E) (EB-001), BONTOXILYSIN-E
  7. Drug

    Ofatumumab

    go.drugbank.com/drugs/DB06650
    ApprovedInvestigational

    It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. … [L12771] It is used in the treatment of recurrent, progressive, or recurrent chronic lymphocytic leukemia (CLL) or CLL in treatment-naive patients in whom fludarabine-based therapy is considered inappropriate

    Products: ARZERRA 100 MG I.V. İNFÜZYONLUK ÇÖZELTİ KONSATRESİ İÇEREN FLAKON (3 ADET), ARZERRA 1000 MG I.V. İNFÜZYONLUK ÇÖZELTİ KONSATRESİ İÇEREN FLAKON (1 ADET)
  8. Drug

    Obinutuzumab

    go.drugbank.com/drugs/DB08935
    ApprovedInvestigational

    [L54521] It was developed as a Type II anti-CD20 antibody to improve upon first-generation agents like rituximab. … [L54521] Like other drugs in its class, obinutuzumab targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes, mediating B-cell lysis.

    Products: GAZYVA 1000 MG/ 40 ML CONCENTRATE FOR SOLUTION FOR INFUSION, GAZYVA 1000 MG IV İNFÜZYONLUK KONSANTRE ÇÖZELTİ, 1 ADET
  9. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    [L64039,L64041] Because it targets a broad range of RAS genotypes, it treats tumors with or without an identified RAS mutation and does not require a companion diagnostic test. … [L64039] It is a RAS(ON) tri-complex inhibitor that binds cyclophilin A and targets the active, GTP-bound ("ON") state of RAS, suppressing signaling of both wild-type and mutant RAS across the most common

  10. Drug

    Trichlormethiazide

    go.drugbank.com/drugs/DB01021
    ApprovedVet approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)